A phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer

Japanese Journal of Clinical Oncology

Volumn 30, Issue 10, 2000, Pages 429-434

  Perng, Reury Perng ^a   Shih, Jen Fu ^a   Chen, Yuh Min ^a,b   Chou, Kuo Chih ^a   Lee, Yu Chin ^a   Tsai, Chun Ming ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Cisplatin; Docetaxel; Non small cell lung cancer; Second line treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN DERIVATIVE; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA;

EID: 0033659144     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyd117     Document Type: Article

References (25)

1. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
2. Docetaxel: A review of its pharmacology and clinical activity
3. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer
4. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer
5. Docetaxel (Taxotere) is active in non-small-cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group
6. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer
7. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer
8. Docetaxel in stage III and IV non-small cell lung cancer
9. Docetaxel: Meeting the challenge of non-small cell lung cancer management
10. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: A Japanese cooperative study
11. A phase II trial of docetaxel in advanced non-small cell lung cancer
12. Management strategies for recurrent non-small cell lung cancer
13. Single agents in the second-line treatment of non-small cell lung cancer
14. Docetaxel in the management of advanced non-small cell lung cancer
15. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: A multicenter phase II trial
16. Phase II study of docetaxel (Taxotere; TXT) in first- and second-line NSCLC
17. Do newer chemotherapeutic agents improve survival in non-small cell lung cancer?
18. Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer
19. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of Eastern Cooperative Oncology Group
20. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group
21. Docetaxel (D) for platinum-refractory non-small cell lung cancer (NSCLC): Comparison of phase II results to historical controls (HC)
22. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
23. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
24. Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial